Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Roche’s Elecsys pTau181 test has secured CE Mark approval, marking a development in ruling out Alzheimer's disease.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) ('Aquestive” or the 'Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science ...

David Mooney, who most recently served as Chief of Cyber Protective Services at the Cybersecurity and Infrastructure Security ...

Aegle Therapeutics, a clinical-stage dermatology-focused biopharmaceutical company developing novel therapies for those ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now.

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term ...

Eli Lilly LLY 1.34% agreed to acquire Verve Therapeutics VERV -0.37% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.

The Eli Lilly case against Empower Pharmacy tests a key strategy that's allowed compounding pharmacies to continue to produce versions of wildly popular drugs.

Key Points Visa, Netflix and Eli Lilly are moving closer to the trillion dollar club. While all three have the potential, one will reach $3 trillion sooner than the others.